PHAS - PhaseBio Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

with an average price target of $4.6. This is a potential upside of $4.6 (0%) from yesterday's end of day stock price of $0.

PhaseBio Pharmaceuticals's activity chart (see below) currently has 27 price targets and 19 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 2.86% with an average time for these price targets to be met of 21.14 days.

Most recent stock forecast was given by ANNABEL SAMIMY from STIFEL on 28-Sep-2022.

Best performing analysts who are covering PHAS - PhaseBio Pharmaceuticals:

Joel Beatty Chad Messer Adam Walsh Annabel Samimy Derek Archila Serge Belanger Phil Nadeau

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$1

$0.96 (2400.00%)

$15

2 years 2 months 1 days ago
(28-Sep-2022)

0/2 (0%)

$0.74 (284.62%)

Buy

3 years 1 months 16 days ago
(13-Oct-2021)

0/1 (0%)

$6.27 (132.56%)

Buy

$15

$14.96 (37400.00%)

3 years 5 months 12 days ago
(17-Jun-2021)

0/3 (0%)

$11.02 (276.88%)

Buy

$10

$9.96 (24900.00%)

$12

4 years 3 months 4 days ago
(25-Aug-2020)

0/6 (0%)

$6.2 (163.16%)

Buy

$14

$13.96 (34900.00%)

$17

4 years 6 months 1 days ago
(28-May-2020)

1/5 (20%)

$7.98 (132.56%)

148

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is PHAS (PhaseBio Pharmaceuticals) average time for price targets to be met?

On average it took 21.14 days on average for the stock forecasts to be realized with a an average price target met ratio 2.86

Which analyst has the current highest performing score on PHAS (PhaseBio Pharmaceuticals) with a proven track record?

JOEL BEATTY

Which analyst has the current lower performing score on PHAS (PhaseBio Pharmaceuticals) with a proven track record?

PHIL NADEAU

Which analyst has the most public recommendations on PHAS (PhaseBio Pharmaceuticals)?

Joel Beatty works at BAIRD and has 3 price targets and 2 ratings on PHAS

Which analyst is the currently most bullish on PHAS (PhaseBio Pharmaceuticals)?

Chad Messer with highest potential upside - $14.96

Which analyst is the currently most reserved on PHAS (PhaseBio Pharmaceuticals)?

Derek Archila with lowest potential downside - -$0

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?